


Amended Claim Set

Please amend the claims in the following manner:

Claim 1. (currently amended) A compound, isomer of the compound, enantiomer of the compound, tautomer of the compound, racemate of the compound, or polymorph of the compound, wherein:

the compound corresponds in structure to [[of]] Formula I:



wherein:

X is selected from the group consisting of:

<p>(1),</p>	<p>(2),</p>
<p>(3), and</p>	<p>(4);</p>

Y is selected from the group consisting of N-R¹, O, and S;

y and z are independently selected from ~~an integer selected from the group consisting of~~ 0, 1, 2, and 3;

A is N or C;

as to R¹:

X corresponds in structure to Formula (1), and R¹ is selected from the group consisting of H, alkyl, [[aryl]] phenyl, hydroxy, alkoxy, cyano, nitro, amino, alkenyl, alkynyl, amido, alkylcarbonyl, ~~arylearbonyl phenylcarbonyl~~, alkoxy carbonyl, ~~aryloxyarbonyl phenyloxycarbonyl~~, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, ~~arylthioarbonyl phenylthiocarbonyl~~, acyloxymethoxycarbonyl, alkyl optionally substituted with one or more substituent substituents selected from the group consisting of lower alkyl, halogen, hydroxyl, haloalkyl, cyano, nitro, carboxyl, amino, alkoxy, phenyl, and phenyl aryl or aryl optionally substituted with one or more substituents selected from the group consisting of halogen, haloalkyl, lower alkyl, alkoxy, cyano, alkylsulfonyl, alkylthio, nitro, carboxyl, amino, hydroxyl, sulfonic acid, sulfonamide, ~~aryl, fused aryl phenyl, naphthyl~~, monocyclic heterocycles, and [[or]] fused monocyclic heterocycles, aryl optionally phenyl substituted with one or more substituent substituents selected from the group consisting of halogen, haloalkyl, hydroxy, lower alkyl, alkoxy, methylenedioxy, ethylenedioxy, cyano, nitro, alkylthio, alkylsulfonyl, sulfonic acid, sulfonamide, carboxyl derivatives, amino, ~~aryl, fused aryl phenyl, naphthyl~~, monocyclic heterocycles, and fused monocyclic heteroeyele heterocycles, monocyclic heterocycles, and monocyclic heterocycles optionally substituted with one or more substituent substituents selected from the group consisting of halogen, haloalkyl, lower alkyl, alkoxy, amino, nitro, hydroxy, carboxyl derivatives, cyano, alkylthio, alkylsulfonyl, sulfonic acid, sulfonamide, ~~aryl or fused aryl phenyl and naphthyl~~; or

X corresponds in structure to Formula (1), and R¹ and R⁸ [[taken]] together with the atoms to which they are bonded, form R⁸ forms a 4-12 membered dinitrogen-containing heterocycle optionally substituted with one or more substituent substituents selected from the group consisting of lower alkyl, hydroxy, [[keto,]] alkoxy, halo, phenyl, amino, carboxyl, [[or]] carboxyl ester, and fused phenyl; or

X corresponds in structure to Formula (1), and R¹ and R⁸, [[taken]] together with the atoms to which they are bonded, form R⁸-forms a 5 membered heteroaromatic ring optionally substituted with one or more substituent substituents selected from the group consisting of lower alkyl, phenyl, and hydroxy; or

X corresponds in structure to Formula (1), and R¹ and R⁸, [[taken]] together with the atoms to which they are bonded, form R⁸-forms a 5 membered heteroaromatic ring fused with a phenyl group; or

X corresponds in structure to Formula (3), and R¹ and R⁸, together with the atoms to which they are bonded, form a 5-8 membered dinitrogen-containing heterocycle optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, phenyl, or carboxyl derivatives; or


X corresponds in structure to Formula (4), and R¹ and R⁸, together with the atoms to which they are bonded, form a 5-8 membered dinitrogen-containing heterocycle optionally substituted with hydroxy, phenyl, or alkyl;

as to R⁸:

X corresponds in structure to Formula (1) or (2), and R⁸ (when not taken together with R¹) and R⁹ are independently is selected from the group consisting of H, alkyl, alkenyl, alkynyl, aralkyl phenylalkyl, amino, alkylamino, hydroxy, alkoxy, arylamino phenylamino, amido, alkylcarbonyl, arylecarbonyl phenylcarbonyl, alkoxy carbonyl, aryloxy, aryloxycarbonyl phenyloxy, phenyloxycarbonyl, haloalkyl carbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, arylthiocarbonyl phenylthiocarbonyl, acyloxymethoxycarbonyl, cycloalkyl, bicycloalkyl, [[aryl]] phenyl, acyl, benzoyl, alkyl optionally substituted with one or more substituent substituents selected from the group consisting of lower alkyl, halogen, hydroxy, haloalkyl, cyano, nitro, carboxyl derivatives, amino, alkoxy, thio, alkylthio, sulfonyl, aryl, aralkyl, aryl optionally phenyl, phenylalkyl, phenyl substituted with one or more substituent substituents selected from the group consisting of halogen, haloalkyl, lower alkyl, alkoxy,

methylenedioxy, ethylenedioxy, alkylthio, haloalkylthio, thio, hydroxy, cyano, nitro, carboxyl derivatives, aryloxy phenyloxy, amido, acylamino, amino, alkylamino, dialkylamino, trifluoroalkoxy, trifluoromethyl, sulfonyl, alkylsulfonyl, haloalkylsulfonyl, sulfonic acid, sulfonamide, aryl, fused-aryl phenyl, naphthyl, monocyclic heterocycles, fused monocyclic heterocycles, phenyl aryl optionally substituted with one or more substituent substituents selected from the group consisting of halogen, haloalkyl, lower alkyl, alkoxy, methylenedioxy, ethylenedioxy, alkylthio, haloalkylthio, thio, hydroxy, cyano, nitro, carboxyl derivatives, aryloxy phenyloxy, amido, acylamino, amino, alkylamino, dialkylamino, trifluoroalkoxy, trifluoromethylsulfonyl, alkylsulfonyl, sulfonic acid, sulfonamide, aryl, fused-aryl phenyl, naphthyl, monocyclic heterocycles, and [(or)] fused monocyclic heterocycles, monocyclic heterocycles, monocyclic heterocycles optionally substituted with one or more substituent substituents selected from the group consisting of halogen, haloalkyl, lower alkyl, alkoxy, aryloxy phenyloxy, amino, nitro, hydroxy, carboxyl derivatives, cyano, alkylthio, alkylsulfonyl, aryl, fused-aryl phenyl, naphthyl, monocyclic and bicyclic heterocyclicalkyls, and $-\text{SO}_2\text{R}^{10}$; or wherein R¹⁰ is selected from the group consisting of alkyl, aryl and monoeyelic heteroeycles, all optionally substituted with one or more substituent selected from the group consisting of halogen, haloalkyl, alkyl, alkoxy, cyano, nitro, amino, acylamino, trifluoroalkyl, amido, alkylaminosulfonyl, alkylsulfonyl, alkylsulfonylamino, alkylamino, dialkylamino, trifluoromethylthio, trifluoroalkoxy, trifluoromethylsulfonyl, aryl, aryloxy, thio, alkylthio, and monoeyelic heteroeycles; and

X corresponds in structure to Formula (1) or (2), and R⁸

is  wherein R¹⁰ is defined as above; or [NR⁸]]

X corresponds in structure to Formula (1), and R⁸ and R⁹, [(taken)] together with the nitrogen to which they are bonded, form a 4-12 membered mononitrogen-containing monocyclic or bicyclic ring, wherein the ring:

is optionally substituted with one or more **substituent**
substituents selected from **the group consisting of** lower alkyl,
carboxyl derivatives, [[aryl]] **phenyl**, and hydroxy, and
may contain an additional optionally contains a
heteroatom selected from the group consisting of O, N, and S; or
X corresponds in structure to Formula (1), and R⁸ and R¹, together
with the atoms to which they are bonded, form a 4-12 membered
dinitrogen-containing heterocycle optionally substituted with one or more
substituents selected from the group consisting of lower alkyl, hydroxy,
alkoxy, halo, phenyl, amino, carboxyl, carboxyl ester, and fused phenyl; or
X corresponds in structure to Formula (1), and R⁸ and R¹, together
with the atoms to which they are bonded, form a 5 membered
heteroaromatic ring optionally substituted with one or more substituents
selected from the group consisting of lower alkyl, phenyl, and hydroxy; or
X corresponds in structure to Formula (1), and R⁸ and R¹, together
with the atoms to which they are bonded, form a 5 membered
heteroaromatic ring fused with a phenyl group; or
X corresponds in structure to Formula (2), and R⁸ and R¹¹, together
with the atoms to which they are bonded, form a 4-12 membered
mononitrogen- and monosulfur- or monooxygen-containing heterocyclic ring
optionally substituted with lower alkyl, hydroxy, phenyl, carboxyl, carboxyl
ester, or fused phenyl; or
X corresponds in structure to Formula (2), and R⁸ and R¹¹, together
with the atoms to which they are bonded, form thiazole, oxazole,
benzoxazole, or benzothiazole; or
X corresponds in structure to Formula (2), Y¹ is carbon such that R⁸
and Y¹, together with the atoms to which they are bonded, form a 4-12
membered mononitrogen- or dinitrogen-containing ring optionally
substituted with alkyl, phenyl, or hydroxy; or
X corresponds in structure to Formula (3), and R⁸ and R¹, together
with the atoms to which they are bonded, form a 5-8 membered


dinitrogen-containing heterocycle optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, phenyl, or carboxyl derivatives;

X corresponds in structure to Formula (4), and R⁸ and R¹, together with the atoms to which they are bonded, form a 5-8 membered dinitrogen-containing heterocycle optionally substituted with hydroxy, phenyl, or alkyl;

as to R⁹:

X corresponds in structure to Formula (1), and R⁹ is selected from the group consisting of H, alkyl, alkenyl, alkynyl, phenylalkyl, amino, alkylamino, hydroxy, alkoxy, phenylamino, amido, alkylcarbonyl, phenylcarbonyl, alkoxy carbonyl, phenoxy, phenoxy carbonyl, haloalkyl carbonyl, haloalkoxy carbonyl, alkylthiocarbonyl, phenylthiocarbonyl, acyloxymethoxycarbonyl, cycloalkyl, bicycloalkyl, phenyl, acyl, benzoyl, alkyl substituted with one or more substituents selected from the group consisting of lower alkyl, halogen, hydroxy, haloalkyl, cyano, nitro, carboxyl derivatives, amino, alkoxy, thio, alkylthio, sulfonyl, phenyl, phenylalkyl, phenyl substituted with one or more substituents selected from the group consisting of halogen, haloalkyl, lower alkyl, alkoxy, methylenedioxy, ethylenedioxy, alkylthio, haloalkylthio, thio, hydroxy, cyano, nitro, carboxyl derivatives, phenoxy, amido, acylamino, amino, alkylamino, dialkylamino, trifluoroalkoxy, trifluoromethyl, sulfonyl, alkylsulfonyl, haloalkylsulfonyl, sulfonic acid, sulfonamide, phenyl, naphthyl, monocyclic heterocycles, fused monocyclic heterocycles, phenyl substituted with one or more substituents selected from the group consisting of halogen, haloalkyl, lower alkyl, alkoxy, methylenedioxy, ethylenedioxy, alkylthio, haloalkylthio, thio, hydroxy, cyano, nitro, carboxyl derivatives, phenoxy, amido, acylamino, amino, alkylamino, dialkylamino, trifluoroalkoxy, trifluoromethylsulfonyl, alkylsulfonyl, sulfonic acid, sulfonamide, phenyl, naphthyl, monocyclic heterocycles, and fused monocyclic heterocycles, monocyclic heterocycles, monocyclic heterocycles substituted with one or

more substituents selected from the group consisting of halogen, haloalkyl, lower alkyl, alkoxy, phenoxy, amino, nitro, hydroxy, carboxyl derivatives, cyano, alkylthio, alkylsulfonyl, phenyl, naphthyl, monocyclic and bicyclic heterocyclicalkyls, and $-\text{SO}_2\text{R}^{10}$; or




or

X corresponds in structure to Formula (1), and R⁹ and R⁸, together with the nitrogen to which they are bonded, form a 4-12 membered mononitrogen-containing monocyclic or bicyclic ring, wherein the ring:

is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, carboxyl derivatives, phenyl, and hydroxy, and may contain an additional heteroatom selected from the group consisting of O, N, and S; or

X corresponds in structure to Formula (3), and R⁹ is selected from the group consisting of alkylcarbonyl, phenylcarbonyl, alkoxy carbonyl, phenoxy carbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, phenylthiocarbonyl, or acyloxymethoxycarbonyl; or

X corresponds in structure to Formula (4), and both R⁹ are selected from the group consisting of alkylcarbonyl, phenylcarbonyl, alkoxy carbonyl, phenoxy carbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, phenylthiocarbonyl, and acyloxymethoxycarbonyl;



Y¹ is selected from the group consisting of alkyl, cycloalkyl, bicycloalkyl, [[aryl]] phenyl, monocyclic heterocycles, alkyl optionally substituted with [[aryl]] phenyl which can also be optionally substituted with one or more

substituent substituents selected from the group consisting of halo, haloalkyl, alkyl, nitro, hydroxy, alkoxy, ~~aryloxy, aryl, or fused aryl~~ optionally phenyloxy, phenyl, and naphthyl, phenyl substituted with one or more substituent substituents selected from the group consisting of halo, haloalkyl, hydroxy, alkoxy, ~~aryloxy, aryl, fused aryl~~ phenyloxy, phenyl, naphthyl, nitro, methylenedioxy, ethylenedioxy, and [[or]] alkyl, alkynyl, alkenyl, -S-R¹¹, and -OR¹¹; or wherein

Y¹ is carbon such that Y¹ and R⁸, together with the atoms to which they are bonded, form a 4-12 membered mononitrogen- or dinitrogen-containing ring optionally substituted with alkyl, phenyl, or hydroxy;

R¹⁰ is selected from the group consisting of alkyl, phenyl, and monocyclic heterocycles, wherein:

any such substituent is optionally substituted with one or more substituents selected from the group consisting of halogen, haloalkyl, alkyl, alkoxy, cyano, nitro, amino, acylamino, trifluoroalkyl, amido, alkylaminosulfonyl, alkylsulfonyl, alkylsulfonylamino, alkylamino, dialkylamino, trifluoromethylthio, trifluoroalkoxy, trifluoromethylsulfonyl, phenyl, phenoxy, thio, alkylthio, and monocyclic heterocycles;

as to R¹¹:

R¹¹ is selected from the group consisting of H, alkyl, ~~aralkyl~~ phenylalkyl, phenyl, alkenyl, and alkynyl, or


R¹¹ and R⁸, [[taken]] together with the atoms to which they are bonded, form R⁸ forms a 4-12 membered mononitrogen- and monosulfur- or monooxygen-containing heterocyclic ring optionally substituted with lower alkyl, hydroxy, [[keto,]] phenyl, carboxyl, [[or]] carboxyl ester, or [[and]] fused phenyl, or

R¹¹ and R⁸, [[taken]] together with the atoms to which they are bonded, form [[R⁸ is]] thiazole, oxazole, benzoxazole, or benzothiazole;


R⁸ is defined as above; or

Y¹ (when Y¹ is carbon) taken together with R⁸ forms a 4-12 membered mononitrogen or dinitrogen-containing ring optionally substituted with alkyl,

~~aryl, keto or hydroxy; or~~



X is ~~wherein R¹ and R⁸ taken together form a 5-8 membered dinitrogen containing heterocycle optionally substituted with one or more substituent selected from the group consisting of lower alkyl, hydroxy, keto, phenyl, or carboxyl derivatives; and R⁹ is selected from the group consisting of alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkylcarbonyl, haloalkoxy carbonyl, alkylthiocarbonyl, arylthiocarbonyl, or acyloxymethoxy carbonyl; or~~




~~wherein R¹ and R⁸ taken together form a 5-8 membered dinitrogen containing heterocycle optionally substituted with hydroxy, keto, phenyl, or alkyl; and R⁹ are both selected from the group consisting of alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkylcarbonyl, haloalkoxy carbonyl, alkylthiocarbonyl, arylthiocarbonyl and acyloxymethoxy carbonyl;~~

R², R³, and R⁴ are independently selected from one or more substituent substituents selected from the group the group consisting of H, alkyl, hydroxy, alkoxy, aryloxy phenyloxy, halogen, haloalkyl, haloalkoxy, nitro, amino, alkylamino, acylamino, dialkylamino, cyano, alkylthio, alkylsulfonyl, carboxyl derivatives, trihaloacetamide, acetamide, aryl, fused aryl phenyl, naphthyl, cycloalkyl, thio, monocyclic heterocycles, fused monocyclic heterocycles, and X; and wherein X is defined above;

R⁵, R⁶, and R⁷ are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, [[aryl]] phenyl, carboxyl derivatives, haloalkyl, cycloalkyl, monocyclic heterocycles, monocyclic heterocycles optionally substituted with alkyl, halogen,

haloalkyl, cyano, hydroxy, ~~aryl, fused-aryl~~ phenyl, naphthyl, nitro, alkoxy, ~~aryloxy~~ phenyloxy, alkylsulfonyl, ~~arylsulfonyl~~ phenylsulfonyl, sulfonamide, thio, alkylthio, carboxyl derivatives, amino, amido, alkyl optionally substituted with one or more substituents selected from the group consisting of halo, haloalkyl, hydroxy, alkoxy, ~~aryloxy~~ phenyloxy, thio, alkylthio, alkynyl, alkenyl, alkyl, ~~arylthio~~ phenylthio, alkylsulfoxide, alkylsulfonyl, ~~arylsulfoxide~~, ~~arylsulfone~~ phenylsulfoxide, phenylsulfonyl, cyano, nitro, amino, alkylamino, dialkylamino, alkylsulfonamide, ~~arylsulfonamide~~ phenylsulfonamide, acylamide, carboxyl derivatives, sulfonamide, sulfonic acid, phosphonic acid derivatives, phosphinic acid derivatives, ~~aryl, arylthio arylsulfoxide, or arylsulfone~~ phenyl, phenylthio, phenylsulfoxide, and phenylsulfone, all of which are optionally substituted on the [[aryl]] phenyl ring with halo, alkyl, haloalkyl, cyano, nitro, hydroxy, carboxyl derivatives, alkoxy, ~~aryloxy~~ phenyloxy, amino, alkylamino, dialkylamino, amido, ~~aryl, fused-aryl~~ phenyl, naphthyl, monocyclic heterocycles, and fused monocyclic heterocycles, monocyclic heterocyclithio, monocyclic heterocyclicsulfoxide, and monocyclic heterocyclic sulfone, which ~~can be~~ is optionally substituted with halo, haloalkyl, nitro, hydroxy, alkoxy, fused-aryl naphthyl, or alkyl, alkylcarbonyl, haloalkylcarbonyl, and phenylcarbonyl, phenyl arylearboxyl, aryl optionally substituted in one or more positions with halo, haloalkyl, alkyl, alkoxy, ~~aryloxy~~ phenyloxy, methylenedioxy, ethylenedioxy, alkylthio, haloalkylthio, thio, hydroxy, cyano, nitro, acyloxy, carboxyl derivatives, carboxyalkoxy, amido, acylamino, amino, alkylamino, dialkylamino, trifluoroalkoxy, trifluoromethylsulfonyl, alkylsulfonyl, sulfonic acid, sulfonamide, ~~aryl, fused-aryl~~ phenyl, naphthyl, monocyclic heterocycles and fused monocyclic heterocycles ; and all isomers, enantiomers, tautomers, racemates or polymorphs thereof.

Claim 2. (currently amended) A compound, isomer, enantiomer, tautomer, racemate, or polymorph according to claim 1, wherein:




z is 1;

y is 0;

R⁵ and R⁶ are each H; and

R⁷ is [[=]] H; alkyl, haloalkyl, carboxyalkyl, alkenyl, alkynyl, and phenyl, optionally substituted with one or more halogen [[atom]] atoms.

Claim 3. (currently amended) A compound, isomer, enantiomer, tautomer, racemate, or polymorph according to claim 1, wherein:









R¹ is selected from the group consisting of H, alkyl, [[aryl]] phenyl, hydroxy, alkoxy, cyano, and nitro; and R⁸ is and R⁹ are H; or







R¹ and R⁸, [[taken]] together with the atoms to which they are bonded, form R⁸ forms a 4-12 membered dinitrogen-containing heterocycle optionally substituted with one or more substituent substituents selected from the group consisting of lower alkyl, hydroxy, [[keto,]] alkoxy, halogen, phenyl, amino, carboxyl, [[or]] carboxyl ester, and fused phenyl; and


R⁹ is H.


Claim 4. (currently amended) A compound, isomer of the compound, enantiomer of the compound, tautomer of the compound, racemate of the compound, or polymorph of the compound, wherein:


the compound selected from the group consisting of:




















and all isomers, enantiomers, tautomers, racemates and polymorphs thereof.

Claim 5. (currently amended) A pharmaceutical composition, wherein the composition comprises: comprising
a compound, isomer, enantiomer, tautomer, racemate, or polymorph of Claim 1; and
, 2, 3, or 4
a pharmaceutically-acceptable carrier.

Claim 6. (currently amended) A method of treating inhibiting a condition treatable mediated by inhibiting or antagonizing [[the]] $\alpha_v\beta_3$ or $\alpha_v\beta_5$ integrin, wherein:
the condition is selected from the group consisting of tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy, and arthritis; and

the method comprises comprising administering a therapeutically-effective amount of a compound, isomer, enantiomer, tautomer, racemate, or polymorph of Claim 1, , 2, 3 or 4.

Claim 7 (canceled).

Please add the following new claims:

Claim 8. (new) A pharmaceutical composition, wherein the composition comprises: a compound, isomer, enantiomer, tautomer, racemate, or polymorph of Claim 2; and a pharmaceutically-acceptable carrier.

Claim 9. (new) A method of treating a condition treatable by inhibiting or antagonizing $\alpha_v\beta_3$ or $\alpha_v\beta_5$ integrin, wherein:

the condition is selected from the group consisting of tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atheroscelosis, macular degeneration, retinopathy, and arthritis; and

the method comprises administering a therapeutically-effective amount of a compound, isomer, enantiomer, tautomer, racemate, or polymorph of Claim 2.

Claim 10. (new) A pharmaceutical composition, wherein the composition comprises: a compound, isomer, enantiomer, tautomer, racemate, or polymorph of Claim 3; and a pharmaceutically-acceptable carrier.

Claim 11. (new) A method of treating a condition treatable by inhibiting or antagonizing $\alpha_v\beta_3$ or $\alpha_v\beta_5$ integrin, wherein:

the condition is selected from the group consisting of tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atheroscelosis, macular degeneration, retinopathy, and arthritis; and

the method comprises administering a therapeutically-effective amount of a compound, isomer, enantiomer, tautomer, racemate, or polymorph of Claim 3.

Claim 12. (new) A pharmaceutical composition, wherein the composition comprises: a compound, isomer, enantiomer, tautomer, racemate, or polymorph of Claim 4; and a pharmaceutically-acceptable carrier.

Claim 13. (new) A method of treating a condition treatable by inhibiting or antagonizing $\alpha_v\beta_3$ or $\alpha_v\beta_5$ integrin, wherein:

the condition is selected from the group consisting of tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atheroscelosis, macular degeneration, retinopathy, and arthritis; and

the method comprises administering a therapeutically-effective amount of a compound, isomer, enantiomer, tautomer, racemate, or polymorph of Claim 4.